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Galectin-3 is an important modulator of several biological functions. It has been implicated in numerous disease conditions,
particularly in the long-term complications of diabetes because of its ability to bind the advanced glycation/lipoxidation end
products that accumulate in target organs and exert their toxic effects by triggering proinflammatory and prooxidant pathways.
Recent evidence suggests that galectin-3 may also participate in the development of obesity and type 2 diabetes. It has been shown
that galectin-3 levels are higher in obese and diabetic individuals and parallel deterioration of glucose homeostasis. Two studies in
galectin-3 knockout mice fed a high-fat diet (HFD) have shown increased adiposity and adipose tissue and systemic inflammation
associated with altered glucose homeostasis, suggesting that galectin-3 negatively modulates the responsiveness of innate and
adaptive immunity to overnutrition. However, these studies have also shown that impaired glucose homeostasis occurs in galectin-3
knockout animals independently of obesity. Moreover, another study reported decreased weight and fat mass in HFD-fed galectin-
3 knockout mice. In vitro, galectin-3 was found to stimulate differentiation of preadipocytes into mature adipocytes. Altogether,
these data indicate that galectin-3 deserves further attention in order to clarify its role as a potential player and therapeutic target
in obesity and type 2 diabetes.
1. Introduction
Galectin-3, a chimera-type member of the galectin family,
has been recently recognized as an important modulator of
biological functions and an emerging player in the pathogen-
esis of common disease conditions, including cancer [1] and
immune/inflammatory [2] and metabolic [3, 4] disorders.
Considerable attention has been paid to the role of galectin-
3 in the onset and progression of long-term complications
of diabetes because of its ability to bind the advanced
glycation end products (AGEs) and advanced lipoxidation
end products (ALEs) that accumulate in target organs and
exert their toxic effects by triggering proinflammatory and
prooxidant pathways [5, 6]. With this respect, galectin-3 was
shown to exert a protective effect toward the development
of renal disease and atherosclerosis in experimental animal
models [3, 4], that is, the opposite of the receptor for AGEs
(RAGE), the first identified AGE receptor, which is known
to mediate AGE/ALE-induced tissue injury [7] and to be
upregulated in the absence of galectin-3 [3, 4]. Recently,
galectin-3 has been implicated also in the development of
metabolic disorders, such as obesity and type 2 diabetes,
though data are still fragmentary [3]. This review article is
concerned with current knowledge on the role of galectin-
3 in metabolic disorders and the mechanism by which this
lectin eventually modulates excess fat mass, adipose tissue
and systemic inflammation, and the associated impairment in
glucose regulation, with a view to highlighting the unresolved
issues that deserve further research.
2. Galectin-3 Structure and Function
Galectin-3 is a 29- to 35-kDa protein consisting of two
domains, the C-terminal carbohydrate recognition domain
(CRD), with highly conserved residues between galectins,
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and the N-terminal domain, with a unique short end
continuing into an intervening proline-glycine-alanine-
tyrosine-rich repeat motif [8]. Galectin-3 is mainly located in
the cytoplasm in quiescent cells, and in the nucleus in repli-
cating cells [9]; it is also secreted into the extracellular space
through a nonclassical secretory pathway [10]. Extracellular
galectin-3 interacts with the 𝛽-galactoside residues of several
glycoproteins via the CRD, and increasing concentrations of
multivalent glycoprotein ligands drive formation of multi-
meric structures, which result in higher order lattices. The
galectin-glycoprotein lattice has been shown to play a role in
the regulation of receptor clustering, endocytosis, and signal-
ing [11]. As a component of the cell surface lattice, galectin-3
also regulates the biogenesis of a subpopulation of clathrin-
independent carriers (CLICs) involved in endocytosis of spe-
cific cargo proteins [12]. This function most likely represents
the mechanism through which galectin-3 regulates tyrosine
kinase and TGF-𝛽 receptors signaling, thereby controlling
important cell functions such as cell migration, transdiffer-
entiation, and fibrogenesis [11, 13]. Moreover, the galectin-3
lattice on the cell surface and its related function in CLIC
biogenesis may play a role in AGE/ALE binding, internal-
ization, and degradation [3]. Intracellular galectin-3 interacts
with ligands mainly via peptide-peptide associations [8].
These structural features enable galectin-3 to participate
in several cell functions via its binding to extracellular
and intracellular proteins and make it a broad-spectrum
biological response modifier [3, 5]. In addition to serving as
an AGE/ALE receptor, galectin-3 is involved in pre-mRNA
splicing [14], regulation of cell cycle [15] and Wnt/𝛽-catenin
signaling [16], and dual modulation of cell adhesion [17]
and immune/inflammatory processes. In particular, galectin-
3 has both pro- and anti-inflammatory effects, which depend
on factors such as inflammatory setting and target cell/tissue
[2, 3]. In acute inflammation, galectin-3 is a key component of
the host defenses and promotes onset of the response against
microbial infections and may affect immune/inflammatory
cells by an autocrine/paracrine mechanism [2]. However,
in chronic inflammation, a condition characterizing both
diabetes and obesity, galectin-3 exerts some proresolution
actions limiting further tissue injury and promoting repair.
Relevant anti-inflammatory effects of galectin-3 include stim-
ulation of T-cell apoptosis [18], inhibition of T-cell growth
and T helper 1 differentiation [19], downregulation of T-
cell receptor-mediated T-cell activation [20], induction of
alternative macrophage activation [21], and promotion of
efferocytosis of apoptotic neutrophils by macrophages [22].
Moreover, galectin-3 induces epithelial-mesenchymal transi-
tion and fibrogenesis, which may favor limitation of inflam-
mation and wound healing [23], unless the fibrotic process
proceeds beyond tissue repair [24, 25]. Finally, galectin-3 has
been recently shown to restrain the inflammatory response
that involves the Toll-like receptor- (TLR-) 2 and 4 and the
proinflammatory cytokines interleukin- (IL-) 1-𝛽 and tumor
necrosis factor-𝛼 in macrophages, an effect that contributes
to delay the course of Wallerian degeneration in peripheral
nerves [26], and to reduce the susceptibility to endotoxin
shock [27]. Conversely, galectin-3/TLR-4 interaction has
been reported to sustain microglia activation [28].
3. Galectin-3 in Obesity and Impaired
Glucose Homeostasis
Obesity and type 2 diabetes are reaching epidemic propor-
tions in the Western world [29] and call for novel pharma-
cological interventions to complement lifestyle modifications
in preventing strategies. The parallel rise in the incidence
and prevalence of these two conditions supports the concept
that overweight and obesity are powerful risk factors for
developing type 2 diabetes [30]. The mechanisms linking
excess fat mass, especially at the visceral level, and impaired
glucose regulation include adipose tissue macrophage infil-
tration and deranged lipid metabolism. These changes result
in the release of cytokines and free fatty acids which cause
insulin resistance and 𝛽-cell dysfunction [31]. Several proin-
flammatory and prooxidant signals have been implicated
in the pathogenesis of obesity, including the AGES/ALEs
through their receptor RAGE [32].
Recently, a wealth of human studies has provided evi-
dence that galectin-3 levels are increased in subjects with obe-
sity and type 2 diabetes, and animal studies have suggested
that galectin-3 may be involved in the onset and progression
of thesemetabolic disorders by acting primarily at the adipose
tissue level.
3.1. Human Studies. In the general population, levels of circu-
lating galectin-3 have been shown to correlate positively with
age, prevalence of obesity, diabetes, hypercholesterolemia,
and hypertension, markers of inflammation, and target
organ damage [33, 34], thus indicating a strict relationship
of galectin-3 with metabolic disorders and associated risk
factors and complications.
A few studies have investigated the relationship between
circulating levels of galectin-3, obesity and parameters of
glucose metabolism, and insulin sensitivity in patients with
diabetes (Figure 1). Weigert et al. [35] reported higher circu-
lating galectin-3 levels in 30 overweight nondiabetic subjects
and 30 patients with type 2 diabetes, in comparison with 23
normal-weight controls. All of them showed galectin-3 levels
that correlated positively with body mass index (BMI), as
well as, in a BMI-dependent manner, with leptin, resistin, IL-
6, and age. In the diabetic population, circulating levels of
galectin-3 correlated inversely with hemoglobin A
1c (HbA1c)
and were higher in subjects with C-reactive protein (CRP)
values above 5mg/L. Finally, galectin-3 levels were higher in
portal vein blood than in blood from hepatic and systemic
veins. This observation suggests that the splanchnic region
constitutes a major site for galectin-3 removal, a finding
consistent with the scavenging role of this lectin in the hepatic
clearance of circulating AGEs [36].
More recently, Yilmaz et al. [37] studied 174 subjects
divided into three groups, nondiabetic, prediabetic, and
diabetic, based on a 75-g oral glucose tolerance test. Galectin-
3 levels were significantly higher in diabetic patients than in
prediabetic and nondiabetic groups and higher in the pre-
diabetic than in the nondiabetic group. Moreover, galectin-
3 levels correlated with fasting plasma glucose (𝑟 = 0.787,
𝑃 < 0.01), 2-hour plasma glucose (𝑟 = 0.833, 𝑃 < 0.01), CRP
(𝑟 = 0.501, 𝑃 < 0.01), and homeostasis model assessment
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Figure 1: Summary of results of human studies on the role of
galectin-3 in impaired glucose regulation and insulin sensitivity.
Solid geometric figures indicate levels of each target, whereas dotted
black lines indicate positive or negative correlation with galectin-
3 levels. In the general population, galectin-3 levels are posi-
tively correlated with HOMA-IR, a measure of insulin resistance.
Conversely, within the diabetic population galectin-3 levels are
negatively correlated to HOMA-IR and HbA
1c levels and positively
with GDR and ISI. HOMA-IR = homeostasis model assessment
of insulin resistance; GDR = glucose disposal rate; ISI = insulin
sensitivity index; HbA
1c = hemoglobin A1c.
of insulin resistance (HOMA-IR) index (𝑟 = 0.518, 𝑃 <
0.01). In multivariate logistic regression analysis galectin-
3 was an independent predictor of diabetes. Moreover, in
receiver operating characteristic analysis, a galectin-3 cut-
off value of 803.55 pg/mL was found to diagnose diabetes
with a sensitivity of 80.7% and a specificity of 85.5% (area
under the curve = 0.912). Yilmaz et al. concluded that
galectin-3 is a promising biomarker for early detection of
prediabetes and diabetes onset and that it has a role in the
progression fromprediabetes to diabetes. However, data from
this cross-sectional study cannot be construed as evidence of
causality between galectin-3 changes and impaired glucose
metabolism. In addition, calculation of HOMA-IR index
is not the most appropriate method to estimate insulin
resistance in this type of studies, where patients with poor
glycemic control, lowBMI, or severe𝛽-cell dysfunction could
be included [38].
A recent study from Ohkura et al. has investigated the
relationship between galectin-3 and insulin sensitivity in
20 patients with type 2 diabetes through the euglycemic-
hyperinsulinemic clamp, the gold standard for the assessment
of insulin sensitivity, a meal tolerance test (MTT), and
HOMA-IR index [39]. Galectin-3 levels correlated positively
with the glucose disposal rate (𝑟 = 0.71, 𝑃 < 0.001),
insulin sensitivity index in MTT (𝑟 = 0.62, 𝑃 < 0.005),
and adiponectin concentration (𝑟 = 0.61, 𝑃 < 0.05)
and negatively with the HOMA-IR index (𝑟 = −0.52,
𝑃 < 0.05) and fasting insulin concentration (𝑟 = −0.56,
𝑃 < 0.01). In MTT, galectin-3 levels were not significantly
associated with the areas under the curve of glucose, insulin,
and the insulin/glucose ratio; a negative, but not significant,
association was reported with insulin and the insulin/glucose
ratio.These data, which should be takenwith caution because
of the small size of the study, prompted the authors to
conclude that galectin-3 affects the concentration of insulin
more than that of glucose and that increase of galectin-3
activity in diabetic subjects could improve insulin sensitivity.
These apparently contrasting results might be reconciled
by claiming a role for galectin-3 upregulation as an adap-
tive mechanism to counteract the progression of metabolic
derangement by favoring glucose disposal. In this view,
galectin-3 levels would increase with development of obesity
and diabetes, thus serving as a marker of these disorders,
in which this lectin exerts a protective effect toward insulin
resistance. This interpretation is consistent with the role
of galectin-3 in favoring AGE/ALE disposal [3, 4], as a
number of studies in nondiabetic individuals have shown
that serum levels of AGEs or of their carbonyl precursors are
independent correlates of insulin resistance, as assessed by
HOMA-IR index [40].
3.2. Animal Studies. Several experimental studies have inves-
tigated the role of galectin-3 in the development of type 2
diabetes (Figure 2) and obesity (Figure 3).
Pejnovic et al. [41] and Pang et al. [42] reported increased
fat accumulation and inflammation at the visceral adipose
tissue and systemic level in association with altered glucose
homeostasis in galectin-3 knockout mice fed a high-fat diet
(HFD). Pejnovic et al. also found that galectin-3 knockout
mice fed aHFDhad increased inflammation in the pancreatic
islets associated with accumulation of AGEs [41], which
might be responsible for the impaired glucose regulation.This
interpretation is consistent with a previous report showing
that aminoguanidine prevents decreased glucose-stimulated
insulin secretion in islets exposed to high glucose concen-
trations [43]. These data support the concept that galectin-
3 primarily decreases the response of innate and adaptive
immunity to overnutrition which leads to adipose tissue
inflammation and oxidative stress, thus protecting against
the obesity-associated type 2 diabetes [41, 42]. This view is
consistent with a major anti-inflammatory effect of galectin-
3 in chronic settings [3], the loss of which results in increased
macrophage infiltration and release of proinflammatory and
prooxidant cytokines at the adipose tissue level that enhances
the metabolic derangements associated with fat accumula-
tion. This interpretation is also in keeping with the finding
that mice lacking RAGE exhibit an opposite response to a
HFD, that is, reduced weight gain and inflammation [44].
However, these data do not explain the mechanism by which
galectin-3 limits the expansion of adipose tissue and this
interpretation has been challenged by other observations.
Firstly, both Pejnovic et al. [41] and Pang et al. [42]
found that blood glucose levels were higher also in galectin-3
knockout fed a standard diet versus the corresponding wild
type mice. Moreover, Pang et al. found that, in these animals,
increased fat mass and systemic inflammation occurred
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Figure 2: Summary of results of animal studies on the role of
galectin-3 in deranged glucose homeostasis and “metabolic” inflam-
mation. Like HFD, galectin-3 ablation induces glucose metabolism
dysregulation and metainflammation. Galectin-3 ablation and HFD
have cumulative effects in inducing metabolic and inflammatory
alterations. Gal-3 = galectin-3; crossed Gal-3 = galectin-3 ablation;
HFD = high-fat diet.
after the development of altered glucose homeostasis, which
was not accompanied by decreased insulin sensitivity [42],
thus suggesting that galectin-3 modulates 𝛽-cell function,
irrespective of obesity-related inflammation. However, there
are conflicting data in the literature on this issue. In fact,
previous studies showed that, in rat pancreatic islets exposed
to IL-1𝛽, galectin-3 is the most upregulated protein and that
its overexpression protects the 𝛽-cells from the cytotoxic
effect of IL-1𝛽 [45]. In contrast, galectin-3 appeared to be
crucial for immune mediated 𝛽-cell damage, as galectin-
3 knockout mice were resistant to multiple low doses of
streptozotocin, a classical model of type 1 diabetes [46].
Secondly, at variance with these earlier studies, Baek et
al. have recently reported that galectin-3 knockout mice had
significantly lower bodyweight and epididymalwhite adipose
tissue and higher expression of adipose triacylglycerol lipase,
the rate-limiting enzyme in fat cell lipolysis, as comparedwith
the corresponding wild type animals after 12-week feeding
with a HFD [47]. Conversely, and again at variance with
Pejnovic et al. [41] and Pang et al. [42], plasma glucose levels
did not differ between the two genotypes, though glucose
metabolism was not thoroughly investigated [47]. Interest-
ingly, decreased body size and epididymal white adipose
tissue were observed also in galectin-3 knockout mice fed a
standard chow for 17 months, with no sign of inflammation
[47]. The authors also showed that galectin-3 knockdown
significantly reduced the differentiation of 3T3-L1 cells into
mature fat cells and the expression of the master regulator of
adipocyte differentiation peroxisome-proliferator-activated
receptor 𝛾 (PPAR𝛾) as well as of CCAAT-enhancer-binding
protein (C/EBP) 𝛼 and C/EBP 𝛽 [41]. Moreover, galectin-
3 was found to interact with PPAR𝛾 and to regulate its
expression and transcriptional activation, thus suggesting
that galectin-3 plays a direct role in adipogenesis through
PPAR𝛾 regulation [47]. Reduced lipid accumulation was
paralleled by decreased fat cell enlargement, indicating that
lower adiposity in galectin-3 knockout mice was not due to
a decrease in fat cell number [47]. Indeed, Pang et al. found
that the mRNA levels of PPAR𝛾 were lower in galectin-3
knockout than in wild type mice and that the fat cell size
did not differ between the two genotypes, irrespective of
diet [42]. The results of the study of Baek et al., though
preliminary, point to a stimulatory role of galectin-3 in
adipogenesis, with the lack of this lectin resulting in reduced
body weight gain in response to HFD and aging. In fact,
in human and mouse adipose tissue, galectin-3 is expressed
not only by macrophages but also by fat cells, where it
is modulated during cell differentiation, with high level in
the preadipocyte fraction and almost nil in differentiated
fat cells [48]. Moreover, recombinant human galectin-3 was
found to stimulate preadipocyte proliferation as well as DNA
synthesis [48]. Unfortunately, Baek et al. did not investigate
whether feeding a HFD induced adipose tissue and systemic
inflammation [47], which appeared to parallel increased fat
mass and to drive deranged glucose homeostasis in previous
reports from Pejnovic et al. [41] and Pang et al. [42].
Altogether, these contrasting findings point to the need
of further investigation on the effect of galectin-3 ablation
on adipose tissue morphology and function and glucose
homeostasis as well as on the response to a HFD.
4. Adipose Tissue in Type 2 Diabetes: Just
a Matter of Quantity? The Role of Galectin-3
The studies in experimental animal models reviewed above
have provided new insights in the relationships between
adipocyte size and glucose homeostasis. Previous observa-
tions point to a critical role of lipid handling capacity of white
adipose tissue in the development of type 2 diabetes. This is
a key concept of the “adipose tissue expandability” theory,
which suggests that increased size of adipocytes, close to a
critical volume, favors diversion of lipids to other tissues, cell
suffering, and consequent activation of proinflammatory and
prooxidant pathways at the tissue and systemic level [49].
This theory has been also used to explain the paradox of
the existence of a subset of individuals with normal insulin
sensitivity despite being obese, on the one hand, and of
lean insulin-resistant/diabetic subjects, on the other hand
[50]. In fact, it has been proposed that white adipose tissue
inflammation and associated insulin resistance are coupled
to adipocyte hypertrophy regardless of fat mass and body
weight. However, this traditional view has been recently
challenged by the evidence that small, not enlarged, fat
cells are associated with the onset of insulin resistance and
inflammation in response to overfeeding [51]. Moreover, in
obese subjects, small fat cells predominate in individuals
with abnormal insulin resistance, whereas larger fat cells are
more numerous in insulin-sensitive subjects [52]. Although
no significant difference in the mean size of the larger cells
was found between the insulin-sensitive and insulin-resistant
individuals, insulin resistance was associated with a higher
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Figure 3: Summary of results of animal studies on the role of galectin-3 in obesity and adipogenesis. Structural and molecular features
of adipose tissue of galectin-3 knockout mice, either fed with NFD or HFD. With NFD, galectin-3 ablation is associated with increased
adiposity. However, fat cell size is not increased and PPAR𝛾 expression is even reduced. With HFD, there are contrasting results on the effect
of galectin-3 ablation on fat mass and body weight. However, galectin-3 ablation is always associated with defective size and/or impaired
ability of adipocytes to respond with an enlargement to the fat overload. These structural features, together with defects in the expression of
adipogenic and lipogenic markers (PPAR𝛾 and ATGL), suggest a regulatory role for galectin-3 in adipogenesis. Gal-3 = galectin-3; crossed
Gal-3 = galectin-3 ablation; NFD = normal-fat diet; HFD = high-fat diet; PPAR𝛾 = peroxisome-proliferator-activated receptor 𝛾; ATGL =
adipose triacylglycerol lipase.
ratio of small to large cells [52]. A key point of this study is that
the expression of genes related to fat cell differentiation and
levels of adiponectin are significantly lower in the insulin-
resistant group compared to the insulin-sensitive group, a
finding suggesting that the increased number of small fat
cells is the consequence of their inability of differentiating
into a mature and functional phenotype [52]. Therefore, an
alternative hypothesis is that the “metabolic buffer” function
of the adipose tissue might be also disrupted by defective
adipogenesis which, by reducing the plasticity of adipose
tissue in terms of ability to store and metabolize lipids,
decreases the threshold of critical volume at which adipocytes
cannot properly cope with the metabolic demand.
The studies in galectin-3 knockout mice reviewed above
showed that these animals (a) are more susceptible to type
2 diabetes when challenged with a HFD without developing
adipocyte hypertrophy and (b) show spontaneous derange-
ment of glucose homeostasis associated with smaller and less
mature adipocytes. These data suggest that animals lacking
galectin-3 respond to increased fat intake with adipocyte
hyperplasia, as the hypertrophic response is impaired [42].
This interpretation is once again consistent with the opposite
finding observed in RAGE null mice fed a HFD, which
displayed smaller adipocytes than wild type littermates, but
reduction in size was much less than reduction in body
weight and fat mass, thus suggesting that the hyperplasic
response was fundamentally impaired in these mice [44].
These observations make the galectin-3 knockout mice a
suitable animalmodel to test the alternative hypothesis which
attributes to small, immature adipocytes a major role in
the development of obesity and associated derangement of
glucose homeostasis.
5. Conclusions
Recently, galectin-3 has been implicated in the development
of type 2 diabetes and obesity. Studies in humans have
shown that galectin-3 concentration is higher in obese and
diabetic individuals and that it increases in conjunction
with unbridled glucose homeostasis. On the other hand,
galectin-3 levels correlated positively with insulin sensitivity
and negatively with HbA
1c levels in patients with type 2
diabetes. Taken together, these data suggest that galectin-3
is a surrogate marker, rather than a mediator of metabolic
disorders, in which it might play a protective role, as part
of an adaptive response. Moreover, galectin-3 appears to be
a modulator of adipogenesis by stimulating differentiation of
preadipocytes into mature adipocytes. The absence of fat cell
enlargement in galectin-3 knockout mice suggests that this
lectin might play a role in the storage capacity of the adipose
tissue. Future studies should test the hypothesis that lack of
galectin-3 accelerates disruption of glucose metabolism by
affecting adipogenesis and lipid storage capacity.
In summary, modulation of galectin-3, an emerging all-
out player in metabolic disorders, deserves further scientific
attention as a novel marker and therapeutic avenue for the
control of metabolic disorders such as diabetes and obesity.
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